Solana Consensus Price Target Raised by 18.18% to $3.32
The average one-year price target for Solana (NASDAQCM:HSDT) has been revised to $3.32 / share. This is an increase of 18.18% from the prior estimate of $2.80 dated August 25, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation by Fintel. The latest targets range from a low of $3.03 to a high of $3.68 / share. The average price target represents an increase of 49.32% from the latest reported closing price of $2.22 / share as of September 11, 2026.
Looking at the historical target trajectory, the mean target was recorded at $3.32 on September 14, 2026, and $2.80 on August 28, 2026. Prior to this, the mean target stood at $3.57 on August 4, 2026, and June 30, 2026. Within the observed twelve-month period, the high mean target was $3.57 on August 4, 2026, while the low mean target was $2.80 on August 28, 2026. Compared to a 90-day baseline date of June 8, 2026, the target has changed by -7.14%.
In terms of price performance, Solana's stock experienced a price change of -0.89% over one week, relative to a baseline close of $2.24 on September 4, 2026. Over a one-month period, the price changed by +27.59% from a baseline close of $1.74 on August 11, 2026. The company's latest earnings report, released on August 14, 2026, showed an actual EPS of -0.08 compared to an estimated EPS of -0.0204. Actual revenue was $2,526,000.00, which was -31.21% below the estimated revenue of $3,672,000.00.
Solana, operating as Helius Medical Technologies, Inc., is headquartered in Newtown, Pennsylvania, USA. The firm operates within the healthcare sector, focusing on neurological wellness and therapy, including its Portable Neuromodulation Stimulator (PoNS) device. Analyst sentiment remains positive, with B. Riley Securities maintaining a Buy rating on September 3, 2026, and previously on August 17, 2026. The recommendation trend for the period of September 1, 2026, shows 2 strong buy, 5 buy, and 1 hold recommendations, which is unchanged from the August 1, 2026, period.
Within the broader Health Care Equipment sub-industry, 23 companies are covered, with 9 experiencing raised targets, 7 lowered, and 7 unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +27.48%. Peer companies in the medical technology and neuromodulation space show mixed target revisions. Boston Scientific experienced a negative target revision, while Abbott Laboratories saw a positive revision, and Medtronic's target remained unchanged.
| Company | Target revision | Implied change |
|---|---|---|
| Medtronic | 0.00% | +10.82% |
| Boston Scientific | -2.24% | +55.15% |
| Abbott Laboratories | +1.43% | +21.78% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.